Frost edit · Free shipping over $70 · Cool essentials
Login Register
glp-1 parkinson's disease

glp-1 parkinson's disease Are we measuring the wrong primary outcome for drugs for Parkinson's? Spoiler alert: the pooled data suggests we should pivot away from a motor outcome. Should we think cognitive, autonomic, sleep GLP-1 drugs tied to lower

SKU: 97051624068
4.0
USD22.09 USD48.09

Pay in 4 interest-free payments of $5.52 Learn more

Shipping Estimate
USA
  • USA
  • CAN

Ships within 48 hours · Estimated delivery Aug 19 - Aug 24

Description

Haghighi et al

glp-1 parkinson's disease Are we measuring the wrong primary outcome for drugs for Parkinson's? Spoiler alert: the pooled data suggests we should pivot away from a motor outcome. Should we think cognitive, autonomic, sleep GLP-1 drugs tied to lower

While the peptide was generally well-tolerated, it failed to perform significantly better than a matching placebo

glp-1 parkinson's disease Are we measuring the wrong primary outcome for drugs for Parkinson's? Spoiler alert: the pooled data suggests we should pivot away from a motor outcome. Should we think cognitive, autonomic, sleep GLP-1 drugs tied to lower

Vinegar improves insulin sensitivity to a high-carbohydrate meal

glp-1 parkinson's disease Are we measuring the wrong primary outcome for drugs for Parkinson's? Spoiler alert: the pooled data suggests we should pivot away from a motor outcome. Should we think cognitive, autonomic, sleep GLP-1 drugs tied to lower

I said, Hey, if it's short lived, that's okay

glp-1 parkinson's disease Are we measuring the wrong primary outcome for drugs for Parkinson's? Spoiler alert: the pooled data suggests we should pivot away from a motor outcome. Should we think cognitive, autonomic, sleep GLP-1 drugs tied to lower

We found no other significant main effects or interactions ( p 0.117)

glp-1 parkinson's disease Are we measuring the wrong primary outcome for drugs for Parkinson's? Spoiler alert: the pooled data suggests we should pivot away from a motor outcome. Should we think cognitive, autonomic, sleep GLP-1 drugs tied to lower

(November 1999)

glp-1 parkinson's disease Are we measuring the wrong primary outcome for drugs for Parkinson's? Spoiler alert: the pooled data suggests we should pivot away from a motor outcome. Should we think cognitive, autonomic, sleep GLP-1 drugs tied to lower
Exchange/Return Notes
  • We offer a 30-day return/exchange service after receiving.
  • Final sale items are not eligible for returns or exchanges.
  • To process your return/exchange, please contact us at [email protected]
  • Please click here for more details>>> Return & Exchange Policy

You may also like

recommand products